Novel licofelone analogs for chronic inflammatory diseases, epithelial cancers
This novel analog targets the COX/LOX pathways for relief of pain and inflammation, without the negative side-effects of typical COX-2 inhibitors (GI, renal, cardiovascular), especially with chronic administration. This technology addresses unwanted side-effects by changing mechanistic activity and enhancing renal clearance, potentially providing a more effective and safer approach for treatment of chronic inflammatory diseases and use as a chemopreventative.
- 15/745,603 (US)
- 16828250.7 (Europe)